Numab Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
80
- Latest Deal Type
-
2ndary - Private
- Investors
-
15
Numab Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop multispecific antibody-based immunotherapies. The company reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics through creating mono or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties, enabling healthcare industries to access their platform for simultaneously engaging multiple targets for chronic inflammation and cancer.
Contact Information
Website
www.numab.comCorporate Office
- Bachtobelstrasse 5
- 8810 Horgen
- Switzerland
Corporate Office
- Bachtobelstrasse 5
- 8810 Horgen
- Switzerland
Numab Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 4. Later Stage VC (Series C) | 09-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 09-Mar-2020 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | $5.16M | $5.16M | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
Numab Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred C | ||||||||
| Preferred C | ||||||||
| Preferred B | 3,412,780 | $0.011124 | $7.17 | $7.17 | 1x | $7.17 | 8.04% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Numab Therapeutics Comparisons
Industry
Financing
Details
Numab Therapeutics Competitors (46)
One of Numab Therapeutics’s 46 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| EpimAb Biotherapeutics | Venture Capital-Backed | Shanghai, China | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Araris | Formerly VC-backed | Zurich, Switzerland | ||||
| aTyr Pharma | Formerly VC-backed | San Diego, CA |
Numab Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Numab Therapeutics Patents
Numab Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024407249-A1 | Antibody binding domains having specificity for lilrb2 | Pending | 22-Dec-2023 | ||
| EP-4574843-A1 | Antibody binding domains having specificity for lilrb2 | Pending | 22-Dec-2023 | ||
| EP-4828740-A1 | Antibody binding domains having specificity for lilrb2 | Pending | 22-Dec-2023 | ||
| WO-2025133389-A1 | Antibody binding domains having specificity for lilrb2 | Inactive | 22-Dec-2023 | ||
| EP-4574844-A1 | Multispecific antibodies having specificity for cd47 and pdl1 | Pending | 22-Dec-2023 | C07K16/2827 |
Numab Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Numab Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BlackRock | Asset Manager | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Forbion | Venture Capital | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority |
Numab Therapeutics FAQs
-
When was Numab Therapeutics founded?
Numab Therapeutics was founded in 2011.
-
Where is Numab Therapeutics headquartered?
Numab Therapeutics is headquartered in Horgen, Switzerland.
-
What is the size of Numab Therapeutics?
Numab Therapeutics has 80 total employees.
-
What industry is Numab Therapeutics in?
Numab Therapeutics’s primary industry is Drug Discovery.
-
Is Numab Therapeutics a private or public company?
Numab Therapeutics is a Private company.
-
What is Numab Therapeutics’s current revenue?
The current revenue for Numab Therapeutics is .
-
How much funding has Numab Therapeutics raised over time?
Numab Therapeutics has raised $228M.
-
Who are Numab Therapeutics’s investors?
BlackRock, BVF Partners, Cormorant Asset Management, Forbion, and HBM Healthcare Investments are 5 of 15 investors who have invested in Numab Therapeutics.
-
Who are Numab Therapeutics’s competitors?
CytomX Therapeutics, EpimAb Biotherapeutics, Adimab, Araris, and aTyr Pharma are some of the 46 competitors of Numab Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
